- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 -
Related Questions
How will the ongoing dosing in the INSPIRE DUCHENNE trial affect SBIO's cash burn and runway?
What are the expected milestones and potential catalysts for SBIO in Q4 2025 regarding FDA discussions?
What regulatory pathways is SBIO considering and how might they influence the commercialization timeline?
Will the Q2 2025 financial results (revenue, R&D expense, net loss) lead to a re‑rating of the stock by analysts?
What is the probability of achieving Breakthrough Therapy designation based on current data and how would that affect valuation?
How might the sentiment score of 45 be interpreted by the market and what short‑term price implications could arise?
How does the enrollment of 15 participants compare to the trial's target size and timeline?
What data readouts are anticipated from the Phase 1/2 trial and when could they impact the stock price?
How does SBIO's trial progress compare to other companies developing Duchenne muscular dystrophy therapies?
Are there any partnership or licensing opportunities on the horizon that could provide additional funding or de‑risk the program?